In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disorder progression or maybe the contributors are not able to tolerate the study drugs. For all move cytometry experiments, ten,000 cells for every replicate https://abbv-744-brd4-inhibitor-c35780.bleepblogs.com/32594433/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc